title: [Clinical evaluation of cefozopran as treatment for febrile neutropenia].
abstract: Clinical effects and safety of cefozopran (CZOP) were evaluated by the Okayama Bone Marrow Transplantation Group. Twenty-five patients expected to experience febrile neutropenia during induction chemotherapy or consolidation chemotherapy of acute leukemia were enrolled between July 2000 and November 2002. CZOP was administrated by drip infusion at 4g/day bid for a minimum of 3 days. The clinical effects and safety were evaluated in 20 patients with fever of 37.5 degrees C or more from a clinically suspected infection. The underlying disease was acute myeloid leukemia in 17 patients, acute lymphoid leukemia in 1 and acute promyelogeneous leukemia in 1. The complicating infections were sepsis and suspected sepsis. Clinical efficacy was excellent in 11 patients, good in 1, fair in 2 and poor in 6, with an efficacy rate of 60.0%. The efficacy rate in patients whose albumin levels before therapy were less than 3.8 g/dl was 37.5%, whereas the rate in patients whose albumin levels before therapy were between 3.8 g/dl and 5.3 g/dl was 80.0%. The efficacy rate in patients whose neutrophil counts before therapy were less than 100/microliter was 50.0%, whereas the rate in patients whose neutrophil counts after therapy were less than 100/microliter was 53.8%. The efficacy rate in patients whose neutrophil counts both before and after therapy were less than 100/microliter was 37.5%. Side effect of exanthema was observed in 1 patient. These results indicate that CZOP is an effective and safe antibiotic for the treatment of febrile neutropenia in patients with hematological malignancies.
authors.affiliation: Dept. of Internal Medicine II, Okayama University Medical School.
authors.forename: Takashi
authors.initials: T
authors.lastname: Saito
authors.forename: Masamichi
authors.initials: M
authors.lastname: Hara
authors.forename: Katsuji
authors.initials: K
authors.lastname: Shinagawa
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Nawa
authors.forename: Koichi
authors.initials: K
authors.lastname: Nakase
authors.forename: Makoto
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Akira
authors.initials: A
authors.lastname: Miyata
authors.forename: Shunnichi
authors.initials: S
authors.lastname: Fukuda
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Sunami
authors.forename: Kenji
authors.initials: K
authors.lastname: Imajoh
authors.forename: Tomofumi
authors.initials: T
authors.lastname: Yano
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kojima
authors.forename: Takanori
authors.initials: T
authors.lastname: Teshima
authors.forename: Nobuharu
authors.initials: N
authors.lastname: Fujii
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Ishimaru
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ikeda
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications*; D000097586:Cefozopran
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097586:Cefozopran